Liyuan Hao, Shenghao Li, Jiali Deng, Na Li, Fei Yu, Zhi Jiang, Junli Zhang, Xinli Shi, Xiaoyu Hu
Frontiers in immunology 2023The application of immunotherapy in tumor, especially immune checkpoint inhibitors (ICIs), has played an important role in the treatment of advanced unresectable liver cancer. However, the efficacy of ICIs varies greatly among different patients, which has aroused people's attention to the regulatory mechanism of programmed death ligand-1 (PD-L1) in the immune escape of liver cancer. PD-L1 is regulated by multiple levels and signaling pathways in hepatocellular carcinoma (HCC), including gene variation, epigenetic inheritance, transcriptional regulation, post-transcriptional regulation, and post-translational modification. More studies have also found that the high expression of PD-L1 may be the main factor affecting the immunotherapy of liver cancer. However, what is the difference of PD-L1 expressed by different types of cells in the microenvironment of HCC, and which type of cells expressed PD-L1 determines the effect of tumor immunotherapy remains unclear. Therefore, clarifying the regulatory mechanism of PD-L1 in liver cancer can provide more basis for liver cancer immunotherapy and combined immune treatment strategy. In addition to its well-known role in immune regulation, PD-L1 also plays a role in regulating cancer cell proliferation and promoting drug resistance of tumor cells, which will be reviewed in this paper. In addition, we also summarized the natural products and drugs that regulated the expression of PD-L1 in HCC. Copyright © 2023 Hao, Li, Deng, Li, Yu, Jiang, Zhang, Shi and Hu.
Liyuan Hao, Shenghao Li, Jiali Deng, Na Li, Fei Yu, Zhi Jiang, Junli Zhang, Xinli Shi, Xiaoyu Hu. The current status and future of PD-L1 in liver cancer. Frontiers in immunology. 2023;14:1323581
PMID: 38155974
View Full Text